TrialFrontiers in immunology2026

Multidimensional efficacy characterization of xeligekimab in moderate-to-severe plaque psoriasis: regional responses, treatment targets, and patient-reported outcomes from a randomized controlled trial.

Kun Huang et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.